Medicare Final CAR-T Policy Eases Coverage Requirements

In its long-awaited final national coverage determination on chimeric antigen receptor T-cell (CAR-T) therapies, the US Centers for Medicare and Medicaid Services dropped the condition it had proposed earlier that Medicare will cover treatment only if patient data is collected following administration through registries or clinical trials.

CMS also backed off previous specifications on what indications would be covered and that treatment must be administered in the...